Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vupanorsen in Statin-Treated Dyslipidemia (TRANSLATE-TIMI 70)
NCT04516291Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
A Phase 2 trial of vupanorsen in dyslipidemia, sponsored by Pfizer. Started Sep 2020; status: completed.
02
Drugs
vupanorsen
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04516291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516291.